Health care shares are mostly higher in mid-day trading amid broader positive investor sentiment, but some exceptions were notable. XenoPort (XNPT) shares are sharply lower in morning trading after it and GlaxoSmithKline (GSK) said GSK1838262/XP13512 (gabapentin enacarbil) did not demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches. Meanwhile, shares of Affymetrix Inc. (AFFX) were sharply lower in morning trading after the company said second-quarter revenue would be below its previous forecast due to lower sales and foreign academic research standing, according to a Reuters report.
Archive for the ‘Affymetrix’ Category
Health Sector Update: July 7, 2010
Saturday, September 4th, 2010The Chart of the Day – Affymetrix, Inc. (AFFX) – 07/23/09
Wednesday, September 1st, 2010
Technical Analyst, Harry’ Boxer’s Chart Analysis of Affymetrix, Inc. (AFFX)
Affymetrix Says Q2 Revenues to Be Lower than Forecast
Saturday, August 28th, 2010
Shares of Affymetrix Inc. (AFFX) are sharply lower in morning trading after the company said second-quarter revenue would be below its previous forecast due to lower sales and foreign academic research standing, according to Reuters. Second quarter revenue is expected to be in the range of $71 to $72 million compared to a previous outlook of $80 to $82 million, the report said. Analysts had expected revenue of $82.1 million, according to a Thomson Reuters poll. “In Europe, we believe our business was impacted by governmental actions taken to address high levels of debt and weakening currencies,” said Chief Executive Kevin King in a statement. Affymetrix shares are down 23.6%, or $1.31, to $4.24.
News Update: Affymetrix Says Q2 Revenues to Be Lower than Forecast; Europe to Blame
Friday, August 27th, 2010
Shares of Affymetrix Inc. (AFFX) are sharply lower in morning trading after the company said second-quarter revenue would be below its previous forecast due to lower sales and foreign academic research standing, according to Reuters. Second quarter revenue is expected to be in the range of $71 to $72 million compared to a previous outlook of $80 to $82 million, the report said. Analysts had expected revenue of $82.1 million, according to a Thomson Reuters poll. “In Europe, we believe our business was impacted by governmental actions taken to address high levels of debt and weakening currencies,” said Chief Executive Kevin King in a statement. Affymetrix shares are down 23.6%, or $1.31, to $4.24.
Visualysing and analysing Affymetrix 3′ IVT microarray data with Subio Platform
Thursday, August 26th, 2010
Importing Affymetrix 3′ IVT microarray data intoSubio Platform. It is a free, technology-independent omics data browser and software platform for sharing analysis results. Its integrated visualization tools greatly help handling complex omics data and revealing biological insight. You can see it more clearly. www.screencast.com For more information. www.subio.jp
Visualizing and Analysing Affymetrix Whole-Transcript microarray data with Subio Paltform
Wednesday, August 25th, 2010
Importing Affymetrix Whole-Transcript microarray data intoSubio Platform. It is a free, technology-independent omics data browser and software platform for sharing analysis results. Its integrated visualization tools greatly help handling complex omics data and revealing biological insight. You can see it more clearly. www.screencast.com For more information. www.subio.jp
Affymetrix Shares Down 25.41% After It Lowered Its Q2 Revenue Guidance (AFFX)
Wednesday, August 25th, 2010
Affymetrix Inc. (NASDAQ:AFFX) shares are trading 25.41% lower at $4.14 after the company said that it expects Q2 revenue to be below its previous forecast due to lower sales and reduced foreign academic research spending, according to a Reuters report. The company now sees total revenue in the range of $71 million to $72 million, down from its previous estimate of $80 million to $82 million, vs. consensus estimates of $82.1 million. CEO Kevin King said, “In Europe, we believe our business was impacted by governmental actions taken to address high levels of debt and weakening currencies.”
Affinity for Affymetrix LIMS by LabCentrix
Monday, August 23rd, 2010
High-quality, best-practice LIMS automation for your Affymetrix lab.Now you can speed lab workflows, increase the availability of accurate sample data, and improve end-to-end throughput of assays using GeneChip® technology. LabCentrix brings you all these capabilities in a single out-of-the-box solution called Affinity for Affymetrix. It’s a pre-configured implementation of the Thermo Scientific Nautilus™ LIMS software, and it’s integrated with the Affymetrix GCOS and AGCC software. www.labcentrix.com
Sun Modular Datacenter Fuels Momentum With New Customer Wins
Friday, August 13th, 2010
Darlene Yaplee, vice president integrated platforms, Sun Microsystems, Inc. discusses Sun Modular Datacenter S20
Course Overview and Introduction: The Biologic Basis for Analysis of Genetic Variants
Thursday, August 12th, 2010
Thomas Pearson, MD, Ph.D. Professor, University of Rochester School of Medicine. Genetics for Epidemiologists: Applications of Human Genomics to Population Sciences, was a short course for investigators and trainees in the field of epidemiology and related population-based sciences. It was conducted by the National Human Genome Research Institute (NHGRI) on May 13-14, 2008 at Northwestern University in Chicago. The goal of Genetics for Epidemiologists (GFE) was to familiarize epidemiologists and population-based researchers with recent developments in the theory and methods of human genetics that might be applied to the study of the distribution, natural history and etiology of diseases in populations. The course consisted of eight one-hour lectures and focused on the interface between genetics and epidemiology. Emphasis was on the application of modern human genome analysis methodologies to studies of human populations through the design, conduct, analysis, and interpretation of studies which effectively answer the epidemiologic question of interest. GFE is co-sponsored by the Office of Population Genomics, NHGRI, and the Department of Preventive Medicine at Northwestern University’s Feinberg School of Medicine. These videocasts are provided as an educational tool for epidemiologic investigators interested in learning more about applying genomics to their work. More: www.genome.gov
